ADVANZ PHARMA SERVICES (UK) LIMITED
Get an alert when ADVANZ PHARMA SERVICES (UK) LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-07-21 (in 2mo)
Last made up 2025-07-07
Watchouts
None on the register
Cash
£700K
-11.5% vs 2023
Net assets
£54M
+1% vs 2023
Employees
97
-8.5% vs 2023
Profit before tax
-£198K
-46.7% vs 2023
Name history
Renamed 4 times since incorporation
- ADVANZ PHARMA SERVICES (UK) LIMITED 2018-10-30 → present
- CONCORDIA INTERNATIONAL RX (UK) LIMITED 2016-06-17 → 2018-10-30
- AMDIPHARM MERCURY COMPANY LIMITED 2013-03-22 → 2016-06-17
- MERCURY PHARMA MANAGEMENT SERVICES LIMITED 2012-03-20 → 2013-03-22
- GOLDSHIELD MANAGEMENT SERVICES LTD 2003-02-26 → 2012-03-20
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £59,579,000 | £56,458,000 | |
| Operating profit | £0 | £0 | |
| Profit before tax | -£135,000 | -£198,000 | |
| Net profit | £44,000 | -£195,000 | |
| Cash | £791,000 | £700,000 | |
| Total assets less current liabilities | — | — | |
| Net assets | £53,353,000 | £53,913,000 | |
| Equity | £53,353,000 | £53,913,000 | |
| Average employees | 106 | 97 | |
| Wages | £16,179,000 | £16,420,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 0.0% | 0.0% | |
| Net margin | 0.1% | -0.3% | |
| Current ratio | 1.83x | 1.86x | |
| Interest cover | 0.00x | 0.00x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of operations as they fall due. In assessing the ability of the Company to continue as a going concern, the directors have taken account of the loss in 2024 of £195, the cumulative profits of £23,104, and the Company's net current assets and net asset position of £52,199 and £53,913, respectively at 31 December 2024.”
Significant events
- “In April 2016, the UK Competition and Markets Authority ("CMA") commenced an investigation into ADVANZ PHARMA Corp. Limited... On 8 May 2025, the Court of Appeal issued its judgment in which it upheld the CMA's findings against the Company and the Group. On 5 June 2025 the Company and the Group filed an application with the Court of Appeal seeking permission to appeal.”
- “The Company and the Group has recorded a provision under IAS 37 amounting to £42,696 (2023: £37,853) in respect of the full CMA fines and associated interest that may become payable (using Bank of England interest rates).”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 16 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| TMF CORPORATE ADMINISTRATION SERVICES LIMITED | Corporate Secretary | 2022-03-16 | — | — |
| FERRY, Melvin Jeremy, Mr. | Director | 2025-02-06 | Jun 1982 | British |
| STICKLER, Andreas | Director | 2022-01-21 | Feb 1971 | German |
Show 16 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| GRIBBON, Angus John | Secretary | 2003-02-26 | 2004-12-03 |
| SULLY, Robert | Secretary | 2018-10-01 | 2022-03-16 |
| SULLY, Robert James | Secretary | 2011-07-25 | 2016-12-31 |
| VENKATESWARAN, Subramanian | Secretary | 2004-12-03 | 2011-06-24 |
| WILLIAMS, David Richard | Secretary | 2016-12-31 | 2018-10-01 |
| SWIFT INCORPORATIONS LIMITED | Corporate Nominee Secretary | 2003-02-26 | 2003-02-26 |
| AHMAD, Adeel | Director | 2016-01-08 | 2022-01-31 |
| BEIGHTON, John, Mr. | Director | 2010-09-08 | 2016-12-31 |
| DUNCAN, Graeme Neville | Director | 2018-11-30 | 2022-01-12 |
| DUNCAN, Graeme Neville | Director | 2016-12-31 | 2018-03-08 |
| KAMATH, Vikram Laxman | Director | 2012-10-23 | 2025-02-06 |
| PATEL, Rakesh Vinodrai | Director | 2003-02-26 | 2010-05-19 |
| RAMAN, Anand | Director | 2011-01-26 | 2012-10-23 |
| SCHWALBER, Philipp Theodor | Director | 2010-03-02 | 2012-04-18 |
| STONE, Lisa | Director | 2010-03-02 | 2012-04-18 |
| VAN TIGGELEN, Antonie Pieter | Director | 2013-09-25 | 2016-01-08 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Mercury Pharma Group Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2021-06-01 | Active |
| The Blackstone Group Inc. | Corporate entity | Shares 25–50%, Voting 25–50% | 2020-03-27 | Ceased 2021-06-01 |
| Mercury Pharma Group Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-08-10 | Ceased 2020-03-27 |
Filing timeline
Last 20 of 136 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-07-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-06-30 | AA | accounts | Accounts with accounts type full | |
| 2025-02-20 | AP01 | officers | Appoint person director company with name date | |
| 2025-02-19 | TM01 | officers | Termination director company with name termination date | |
| 2024-09-02 | AA | accounts | Accounts with accounts type full | |
| 2024-07-31 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-08-17 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2023-08-03 | AA | accounts | Accounts with accounts type full | |
| 2023-08-02 | CH01 | officers | Change person director company with change date | |
| 2023-08-01 | AD01 | address | Change registered office address company with date old address new address | |
| 2023-07-26 | CH04 | officers | Change corporate secretary company with change date | |
| 2023-07-26 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-07-21 | CH01 | officers | Change person director company with change date | |
| 2022-09-30 | AA | accounts | Accounts with accounts type full | |
| 2022-07-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-03-28 | TM02 | officers | Termination secretary company with name termination date | |
| 2022-03-28 | AP04 | officers | Appoint corporate secretary company with name date | |
| 2022-02-03 | AP01 | officers | Appoint person director company with name date | |
| 2022-02-02 | TM01 | officers | Termination director company with name termination date | |
| 2022-01-26 | TM01 | officers | Termination director company with name termination date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
-5.2%
£59,579,000 £56,458,000
-
Cash
-11.5%
£791,000 £700,000
-
Net assets
+1%
£53,353,000 £53,913,000
-
Employees
-8.5%
106 97
-
Profit before tax
-46.7%
-£135,000 -£198,000
-
Wages
+1.5%
£16,179,000 £16,420,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers